- Overview of current follicular lymphoma (FL) treatment landscape
- Existing and emerging clinical data of available PI3K Inhibitors used for the treatment of relapsed/refractory (R/R) FL
- Selecting and sequencing PI3K inhibitors in the R/R setting
- The evolving role of PI3K inhibitors for patients with FL
Date / Time
John Burke, MD
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Nathan Fowler, MD
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
The goal of this program is to improve the knowledge and competence of learners to optimally use PI3K inhibitor therapy in the management of patients with relapsed/refractory follicular lymphoma.
This educational program is intended for medical oncologists, hematologists, and other healthcare providers who treat patients with follicular lymphoma.
Upon completion of this activity, participants should be able to:
- Integrate current evidence and best practice recommendations plus patient-related and disease-related characteristics to select patients who are candidates to receive PI3K inhibitors for the treatment of R/R FL
- Select appropriate PI3K inhibitor therapy for individual patients during the COVID-19 pandemic based on comorbidities, risk of exposure, adverse event profiles, and mode and frequency of administration
- Describe key differences among available PI3K inhibitors regarding target, indication, clinical trial safety and efficacy data, and dosing and administration used for the treatment of R/R FL
- Monitor for and manage adverse events of treatment in patients with R/R FL being treated with PI3K inhibitors to support quality of life and continuation of treatment
- Apply emerging clinical trial findings on novel therapies when formulating treatment recommendations for PI3K inhibitors for patients with FL in the frontline and R/R settings
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.